-
2023-504331-41-00
5
2024-08-02
Respiratory tract diseases - Wheezing, Asthma
-
2023-508359-38-00
5
2024-06-05
Early-stage Non-squamous Non-small Cell Lung Cancer
-
2023-508456-18-00
6
2024-04-29
Uncomplicated bacteremia caused by E. faecalis or E. faecium.
-
2023-503288-40-00
5
2024-01-26
Unresectable or Metastatic Melanoma
-
2023-504273-21-00
4
2023-10-31
Multiple Myeloma
-
2023-507015-35-00
5
2023-10-06
Coronary Artery Disease
-
2024-515047-31-00
5
2023-08-28
Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC) at stage
-
2022-501024-20-00
5
2023-07-25
ER+/HER2- Early Breast Cancer
-
2024-512359-19-00
4
2023-05-12
Resectable Non-small cell lung cancer Pancoast tumor
-
2023-503444-13-00
5
2023-03-29
Relapsed/refractory multiple myeloma
-
2024-515637-14-00
5
2022-11-08
Cystic Fibrosis
-
2024-517008-12-00
5
2022-10-14
Newly-diagnosed multiple myeloma (NDMM)
-
2023-503467-41-00
5
2022-10-12
Relapsed or Refractory Multiple Myeloma
-
2024-514630-21-00
4
2022-08-11
HER2 positive (HER2+), Hormone Receptor positive (HR+) Early-stage Bre
-
2024-512127-36-00
9
2022-03-31
Non-Small Cell Lung Cancer
-
2023-509133-39-00
5
2021-11-29
Hormone receptor positive, HER2-negative advanced breast cancer
-
2024-510735-21-00
5
2021-11-26
Atherosclerotic cardiovascular disease (ASCVD)
-
2024-516039-28-00
6
2021-09-28
Spontaneous Coronary Artery Dissection.
-
2022-500237-92-00
5
2021-04-23
Newly-diagnosed high-intermediate and high-risk diffuse large B-cell l
-
2023-507188-21-00
5
2021-04-20
Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder
-
2023-503568-18-00
5
2021-04-13
Early human epidermal growth factor receptor 2 (HER2) positive breast
-
2023-505852-23-00
5
2020-11-12
High risk recurrent prostate cancer previously treated with radical pr
-
2023-506365-64-00
5
2020-10-16
Deleterious Germline or Somatic Homologous Recombination Repair (HRR)
-
2023-508830-33-00
4
2019-12-13
Patients diagnosed with advanced or metastatic cancer treated with Tra